{"schema_version":"secwatch.filing_event.v1","accession":"0001576280-23-000059","form_type":"8-K","ticker":"GH","cik":"0001576280","company_name":"Guardant Health, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.479078+00:00","generated_at":"2026-06-15T09:07:34.536971+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Guardant Health Q1 revenue up 34% to $128.7M; raises FY2023 guidance to $535-545M","bullets":["Revenue $128.7M (+34% YoY); clinical tests 39,100 (+45%), biopharma tests 6,150 (+21%).","Net loss $133.5M ($1.30/share) vs $123.2M ($1.21) prior year; non-GAAP net loss $108.5M ($1.06).","Gross margin 59% (down from 67%) on mix shift; operating expenses $209.7M (+12%).","FY2023 revenue guidance raised to $535-545M (prev $525-540M); expects FCF outflow ~$350M.","Appointed Ines Dahne-Steuber COO and promoted Darya Chudova CTO; Shield CRC screening PMA under FDA review."],"urls":{"canonical":"https://secwatch.observer/filing/0001576280-23-000059","json":"https://secwatch.observer/filing/0001576280-23-000059.json","markdown":"https://secwatch.observer/filing/0001576280-23-000059.md","text":"https://secwatch.observer/filing/0001576280-23-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576280/000157628023000059/0001576280-23-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576280/000157628023000059/gh-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:07:34.536971+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d00c8ca49a0d443510c4f1d9a3e76298bc2cfc53","claim":"Guardant Health, Inc. reported the fiscal quarter and year ended March 31, 2023 results: revenue $128.7 million, net income Net loss was $133.5 million, EPS Net loss per share was $1.30. Guidance raised.","evidence_excerpt":"tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2023. First Quarter 2023 Financial Highlights • Revenue of $128.7 million for the first quarter of 2023, an increase of 34% over the first quarter of 2022 • Reported 39,100 tests to clinical customers and 6,150 tests to biopharmaceutical customers in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576280/000157628023000059/0001576280-23-000059-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter and year ended March 31, 2023"},{"label":"Revenue","value":"$128.7 million"},{"label":"Net income","value":"Net loss was $133.5 million"},{"label":"EPS","value":"Net loss per share was $1.30"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ebc4f577561df114920e35398412db26ec008ab2","claim":"Guardant Health, Inc. reported the quarter ended March 31, 2023 results: revenue $128.7 million, net income net loss was $133.5 million, EPS Net loss per share was $1.30. Guidance raised.","evidence_excerpt":"tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2023. First Quarter 2023 Financial Highlights • Revenue of $128.7 million for the first quarter of 2023, an increase of 34% over the first quarter of 2022 • Reported 39,100 tests to clinical customers and 6,150 tests to biopharmaceutical customers in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576280/000157628023000059/0001576280-23-000059-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$128.7 million"},{"label":"Net income","value":"net loss was $133.5 million"},{"label":"EPS","value":"Net loss per share was $1.30"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}